- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02419820
Dose-escalation, Repeated and Single Oral Dosing Study
11. februar 2019 opdateret af: IlDong Pharmaceutical Co Ltd
Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Temanogrel Co-administered With Aspirin and Clopidogrel
Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of APD791 (Temanogrel) Co-administered with Aspirin and Clopidogrel.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
- To investigate pharmacokinetic and pharmacodynamic characteristics of Temanogrel when orally co-administered with Aspirin and/or Clopidogrel in healthy subject. a person determined to be suitable for the purpose of this clinical trial by investigator with consideration for the age and the health status of a volunteer is selected
- Assess the safety of Temanogrel when orally co-administered with Aspirin and/or Clopidogrel in healthy subjects.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
104
Fase
- Fase 1
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
20 år til 45 år (Voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Han
Beskrivelse
Inclusion Criteria:
- a healthy adult between 20 and 45 years old at the time of visit for screening
- a person who is able to give written consent
- a person between 50 and 85 kg at the time of visit for screening
- a woman who is negative on a serum hCG test at the time of visit and the day before a trial, and who is not nursing, a woman who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, or who had a contraceptive operation no later than 120 days before visit for screening, or who is menopausal, a man who had a contraceptive operation no later than 120 days before visit for screening, or who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, and also agree not to donate sperm
- a person more than hemoglobin 12 g/dL at the time of screening (a woman more than hemoglobin 11 g/dL)
- a person whose vital signs were in the normal range at the time of visit for screening, or who is medically determined not to be clinically significant by an investigator
Exclusion Criteria:
- a person with the medical history of gastric ulcer, duodenal ulcer or esophageal ulcer within 90 days from the time of visit for screening
- a person with the medical history of gastrointestinal diseases(e.g. Crohn's disease, ulcerative colitis, etc.) or surgery(excluding uncomplicated appendectomy or herniotomy) affecting the absorption of a clinical trial drug
- a person with the medical history of blood coagulation disorder or hemorrhagic diseases, or with clinically significant abnormal findings decided by a investigator on blood coagulation test at the time of screening
- a woman with the medical history of dysfunctional uterine bleeding within a year from the time of visit for screening
- a person with the medical history of epilepsy or convulsion
- a person with the medical history of internal organ transplant
- a person expected to be hard to complete a clinical trial because of surgery or medical procedures planned within a clinical trial period
- a person with the medical history of clinically significant new diseases within 30 days from the time of visit for screening according to investigator's decision
- a person with hypersensitivity reaction to a drug or gelatin, or the medical history of clinically significant hypersensitivity reaction
- a person with the history of drug abuse, or with a positive reaction to a drug possible to be abused on urine drug screening
- a person with the medical history of alcohol abuse within two years from the time of visit for screening
- a person who is a smoker, or with a positive reaction on a urine nicotine test conducted at the time of visit for screening
- a person who donated whole blood within 60 days or constituents of blood within 30 days, or received a blood transfusion within 30 days from the time of visit for screening
- a person taking other clinical trial drugs within 90 days from the time of visit for screening
- a person taking a prescription drug within 30 days, or a contraindicated drug or oriental medicine within 14 days from the time of visit for screening
- a person with a positive reaction to a serum test(hepatitis B test, hepatitis C test, HIV test, syphilis test)
- a person with hepatic enzymes(AST, ALT) more than 2.5 times of the reference upper limit(UNL) or total bilirubin more than 1.5 times of the reference upper limit(UNL) or creatinine more than 1.25 times of the reference upper limit(UNL)
- a person expected to be hard to complete a clinical trial due to physical or mental status according to investigator's medical decision at the time of visit for screening
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Screening
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: APD791 10mg single dose
|
Temanogrel
Andre navne:
|
|
Eksperimentel: APD791 20mg single dose
|
Temanogrel
Andre navne:
|
|
Eksperimentel: APD791 40mg single dose
|
Temanogrel
Andre navne:
|
|
Eksperimentel: APD791 10mg
APD791 10mg single dose + Aspirin + Clopidogrel
|
Clopidogrel
Andre navne:
Temanogrel
Andre navne:
Aspirin
Andre navne:
|
|
Eksperimentel: APD791 20mg
APD791 20mg single dose + Aspirin + Clopidogrel
|
Clopidogrel
Andre navne:
Temanogrel
Andre navne:
Aspirin
Andre navne:
|
|
Eksperimentel: APD791 40mg
APD791 40mg single dose + Aspirin + Clopidogrel
|
Clopidogrel
Andre navne:
Temanogrel
Andre navne:
Aspirin
Andre navne:
|
|
Eksperimentel: APD791 80mg
APD791 80mg single dose + Aspirin + Clopidogrel
|
Clopidogrel
Andre navne:
Temanogrel
Andre navne:
Aspirin
Andre navne:
|
|
Eksperimentel: APD791 160mg
APD791 160mg single dose + Aspirin + Clopidogrel
|
Clopidogrel
Andre navne:
Temanogrel
Andre navne:
Aspirin
Andre navne:
|
|
Eksperimentel: APD791 240mg
APD791 240mg single dose + Aspirin + Clopidogrel
|
Clopidogrel
Andre navne:
Temanogrel
Andre navne:
Aspirin
Andre navne:
|
|
Eksperimentel: APD791 320mg
APD791 320mg single dose + Aspirin + Clopidogrel
|
Clopidogrel
Andre navne:
Temanogrel
Andre navne:
Aspirin
Andre navne:
|
|
Placebo komparator: APD791 Placebo
APD791 placebo for single dose + Aspirin + Clopidogrel
|
Clopidogrel
Andre navne:
Temanogrel
Andre navne:
Aspirin
Andre navne:
Placebo for APD791
Andre navne:
|
|
Eksperimentel: APD791 2mg MD
APD791 2mg multiple dose + Aspirin + Clopidogrel
|
Clopidogrel
Andre navne:
Temanogrel
Andre navne:
Aspirin
Andre navne:
|
|
Eksperimentel: APD791 5mg MD
APD791 5mg multiple dose + Aspirin + Clopidogrel
|
Clopidogrel
Andre navne:
Temanogrel
Andre navne:
Aspirin
Andre navne:
|
|
Eksperimentel: APD791 10mg MD
APD791 10mg multiple dose + Aspirin + Clopidogrel
|
Clopidogrel
Andre navne:
Temanogrel
Andre navne:
Aspirin
Andre navne:
|
|
Eksperimentel: APD791 20mg MD
APD791 placebo for multiple dose + Aspirin + Clopidogrel
|
Clopidogrel
Andre navne:
Temanogrel
Andre navne:
Aspirin
Andre navne:
|
|
Placebo komparator: APD791 placebo MD
APD791 placebo for multiple dose + Aspirin + Clopidogrel
|
Clopidogrel
Andre navne:
Temanogrel
Andre navne:
Aspirin
Andre navne:
Placebo for APD791
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Pharmacokinetics-Cmax
Tidsramme: Day1, Day2, Day3, Day4, Day 7
|
Day1, Day2, Day3, Day4, Day 7
|
|
Pharmacokinetics-Tmax
Tidsramme: Day1, Day2, Day3, Day4, Day 7
|
Day1, Day2, Day3, Day4, Day 7
|
|
Pharmacodynamics-% inhibition of serotonin-stimulated platelet aggregation
Tidsramme: Day1, Day2, Day4, Day7, Day 8
|
Day1, Day2, Day4, Day7, Day 8
|
|
Pharmacodynamics-change of serotonin-stimulated platelet aggregation
Tidsramme: Day1, Day4, Day7
|
Day1, Day4, Day7
|
|
Pharmacodynamics-% inhibition of TRAP-induced platelet aggregation
Tidsramme: Day1, Day4, Day7 of every dose for mutiple dose group and first day for single dose group.
|
Day1, Day4, Day7 of every dose for mutiple dose group and first day for single dose group.
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
adverse event monitoring
Tidsramme: up to post-study visit(8day±2)
|
up to post-study visit(8day±2)
|
|
physical examination
Tidsramme: up to post-study visit(8day±2)
|
up to post-study visit(8day±2)
|
|
vital signs
Tidsramme: up to post-study visit(8day±2)
|
up to post-study visit(8day±2)
|
|
ECG
Tidsramme: up to post-study visit(8day±2)
|
up to post-study visit(8day±2)
|
|
laboratory test
Tidsramme: up to post-study visit(8day±2)
|
up to post-study visit(8day±2)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Gyunseop Bae, M.D., Asan Medical Center
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. marts 2015
Primær færdiggørelse (Faktiske)
1. april 2016
Studieafslutning (Faktiske)
1. april 2016
Datoer for studieregistrering
Først indsendt
27. januar 2015
Først indsendt, der opfyldte QC-kriterier
16. april 2015
Først opslået (Skøn)
17. april 2015
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
15. februar 2019
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
11. februar 2019
Sidst verificeret
1. februar 2019
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Myokardieiskæmi
- Hjertesygdomme
- Hjerte-kar-sygdomme
- Karsygdomme
- Akut koronarsyndrom
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Agenter fra det perifere nervesystem
- Enzymhæmmere
- Analgetika
- Sensoriske systemagenter
- Anti-inflammatoriske midler, ikke-steroide
- Analgetika, ikke-narkotisk
- Anti-inflammatoriske midler
- Antirheumatiske midler
- Fibrinolytiske midler
- Fibrinmodulerende midler
- Blodpladeaggregationshæmmere
- Cyclooxygenase-hæmmere
- Antipyretika
- Purinerge P2Y-receptorantagonister
- Purinerge P2-receptorantagonister
- Purinerge antagonister
- Purinerge midler
- Serotoninmidler
- Serotonin 5-HT2-receptorantagonister
- Serotonin-antagonister
- Aspirin
- Clopidogrel
- APD791
Andre undersøgelses-id-numre
- ID-TMG-102
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Akut koronarsyndrom
-
IRCCS Policlinico S. DonatoRekrutteringAnomalous aorta origin of the coronary artery (AAOCA)Italien
-
GlaxoSmithKlineIkke rekrutterer endnu
-
IRCCS Policlinico S. DonatoUniversity of Pavia; University of Naples; The Mediterranean Institute for...RekrutteringMyokardieiskæmi | Pludselig hjertedød | Anomal koronararterieoprindelse | Anomal koronararterie, der opstår fra den modsatte sinus | Anomal koronararterie med aorta-oprindelse og forløb mellem de store arterier | Anomalous aorta origin of the coronary artery (AAOCA) | Myokardieiskæmi, Angina Pectoris og andre forholdItalien
-
Unravel Biosciences, Inc.RekrutteringPitt Hopkins syndromColombia
-
Helen Keller Eye Research FoundationFive Lakes Clinical Research Consulting, LLCRekrutteringStickler syndrom type 2 | Stickler syndrom type 1Forenede Stater
-
University of California, Los AngelesBoston Children's Hospital; Duke University; Children's Hospital Medical...RekrutteringBohring-Opitz syndrom | ASXL1 genmutation | Shashi-Pena syndrom | ASXL2-genmutation | Bainbridge-Ropers syndrom | ASXL3 genmutationForenede Stater
-
Neuren Pharmaceuticals LimitedRekrutteringPhelan-McDermid syndromForenede Stater
-
University of California, DavisNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AfsluttetTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapi-relateret myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært højrisiko myelodysplastisk syndromForenede Stater
-
Neuren Pharmaceuticals LimitedRekrutteringPhelan-McDermid syndromForenede Stater
-
Riphah International UniversityAfsluttet
Kliniske forsøg med Clopidogrel
-
Chinese PLA General HospitalUkendtCLOPIDOGREL, DÅRLIG METABOLISME af (lidelse)Kina
-
Korea University Anam HospitalAfsluttet
-
Fondation Hôpital Saint-JosephIkke rekrutterer endnuCLTI defineret som Rutherford kategori 4 eller 5
-
Ospedale San DonatoAfsluttet
-
University of PecsAfsluttetStabil Angina Pectoris | Ad hoc perkutan koronar interventionUngarn
-
University of North Carolina, Chapel HillAfsluttet
-
Hospital Central San Luis Potosi, MexicoUkendtAkut koronarsyndrom
-
Deutsches Herzzentrum MuenchenAfsluttetKoronararteriesygdomTyskland
-
Lady Reading Hospital, PakistanPakistan Chest Society, PakistanRekrutteringKOL | KOL-eksacerbation AkutPakistan